|
|
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) |
|
Price: $251.0600
$3.55 
1.434%
|
| Day's High:
| $251.7899932861328
| Week Perf:
| -5.66 %
|
| Day's Low: |
$ 246.01 |
30 Day Perf: |
12.11 % |
| Volume (M): |
243,590 |
52 Wk High: |
$ 495.55 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$345.23 |
| Open: |
$248.05 |
52 Wk Low: |
$197.81 |
|
|
| Market Capitalization (Millions $) |
34,703 |
| Shares
Outstanding (Millions) |
138 |
| Employees |
2,500 |
| Revenues (TTM) (Millions $) |
4,287 |
| Net Income (TTM) (Millions $) |
577 |
| Cash Flow (TTM) (Millions $) |
690 |
| Capital Exp. (TTM) (Millions $) |
72 |
Business Description
Alnylam Pharmaceuticals Inc. is a biotechnology company that specializes in the development of RNA interference (RNAi) therapeutics. RNAi is a natural cellular process that controls the expression of genes, and Alnylam's approach is to use this process to treat various diseases. The company's platform allows for the specific silencing of disease-causing genes, preventing them from producing proteins that cause harm.
Alnylam was founded in 2002 and is based in Cambridge, MA. The company has a strong pipeline of RNAi therapeutic programs, with a focus on genetic diseases, liver diseases, and central nervous system (CNS) disorders. Its lead program is Givlaari (givosiran), a treatment for acute hepatic porphyria (AHP), a rare and life-threatening genetic disease.
Alnylam's pipeline also includes a treatment for hemophilia A and B, a rare genetic bleeding disorder, and a treatment for ATTR amyloidosis, a condition that causes a buildup of abnormal proteins in the body's organs and tissues. The company has several other preclinical and clinical programs in development for a broad range of diseases.
Alnylam has partnered with several pharmaceutical companies, including Sanofi and Regeneron, to develop RNAi therapeutics. The company has also established collaborations with academic institutions and research organizations to advance its platform and expand its pipeline.
Alnylam has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has reported positive financial results in recent quarters, with revenue increasing year over year. Alnylam also received approval for its first RNAi therapeutic, Onpattro (patisiran), in 2018, marking a significant milestone in the company's history.
Overall, Alnylam Pharmaceuticals Inc. is a leading biotechnology company in the RNAi therapeutics space, with a strong pipeline and a focus on developing treatments for rare diseases. The company's innovative approach to gene silencing has the potential to offer significant benefits to patients with a range of conditions.
Company Address: 675 West Kendall Street, Cambridge 2142 MA
Company Phone Number: 551-8200 Stock Exchange / Ticker: NASDAQ ALNY
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Sat, Aug 30 2025 4:46 PM UTC
In a significant advancement in the treatment of uncontrolled hypertension, Genentech, a member of the Roche Group, and Alnylam Pharmaceuticals have announced their decision to initiate a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an innovative RNA interference (RNAi) therapeutic. This development follows encouraging results from the KARDIA Phase II prog...
|
| Business Update
Published Tue, Aug 12 2025 4:31 AM UTC
CAMBRIDGE, Massachusetts In a remarkable stride toward revolutionizing healthcare, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is setting the stage to unveil groundbreaking innovations at the forthcoming European Society of Cardiology (ESC) Congress 2025. This prestigious event, scheduled from August 29 to September 1 in Madrid, Spain, will serve as the platform for Alnyl...
|
| Business Update
Published Sun, May 18 2025 10:42 AM UTC
Alnylam Pharmaceuticals Inc. recently presented additional data from the HELIOS-B clinical trial, highlighting the significant benefits of its drug, AMVUTTRA (vutrisiran), for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The results indicate a marked reduction in both mortality and a variety of significant cardiovascular events among treated patients, unders...
|
| Business Update
Published Fri, Mar 28 2025 11:49 PM UTC
In a groundbreaking development that promises to redefine treatment standards, Alnylam Pharmaceuticals, Inc. has recently achieved a significant milestone in the realm of RNA interference (RNAi) therapeutics. The U.S. Food and Drug Administration (FDA) has granted approval for Qfitlia (fitusiran), marking it as the first siRNA therapeutic approved for the treatment of Hemoph...
|
| Business Update
Published Fri, Mar 21 2025 5:32 PM UTC
Alnylam Pharmaceuticals Breakthrough Approval: AMVUTTRA for ATTR-CM Garners FDA Nod Alnylam Pharmaceuticals Leads Innovation in RNAi Therapeutics with AMVUTTRA and Promising Research on Nucresiran Alnylam Pharmaceuticals, Inc. a pioneer in the development of RNA interference (RNAi) therapeutics, has announced the U.S. Food and Drug Administration s (FDA) approval of their ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
3.93 $ |
| Revenues (TTM) |
31.01 $
|
| Cash Flow (TTM) |
4.99 $ |
| Cash |
21.77 $
|
| Book Value |
7.78 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,714,769 |
| Net
Income per Employee (TTM) |
230,887 |
| Receivable Turnover Ratio (TTM) |
5.37 |
| Inventory Turnover Ratio (TTM) |
10.38 |
| Asset Turnover Ratio (TTM) |
0.88 |
|
|
| Per Share |
|
| Earnings (TTM) |
3.93 $
|
| Revenues (TTM) |
31.01 $ |
| Cash Flow (TTM) |
4.99 $ |
| Cash |
21.77 $
|
| Book Value |
7.78 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Net product revenues |
|
 88.77 % |
of total Revenue |
| Total TTR |
|
78 % |
of total Revenue |
| AMVUTTRA |
|
76.25 % |
of total Revenue |
| ONPATTRO |
|
1.75 % |
of total Revenue |
| Total Rare |
|
10.77 % |
of total Revenue |
| GIVLAARI |
|
6.37 % |
of total Revenue |
| OXLUMO |
|
4.4 % |
of total Revenue |
| United States AMVUTTRA |
|
60.19 % |
of total Revenue |
| United States ONPATTRO |
|
0.87 % |
of total Revenue |
| United States GIVLAARI |
|
4.21 % |
of total Revenue |
| United States OXLUMO |
|
1.45 % |
of total Revenue |
| Europe AMVUTTRA |
|
9.71 % |
of total Revenue |
| Europe ONPATTRO |
|
0.65 % |
of total Revenue |
| Europe GIVLAARI |
|
1.74 % |
of total Revenue |
| Europe OXLUMO |
|
2.09 % |
of total Revenue |
| Rest of World AMVUTTRA |
|
6.35 % |
of total Revenue |
| Rest of World ONPATTRO |
|
0.24 % |
of total Revenue |
| Rest of World GIVLAARI |
|
0.43 % |
of total Revenue |
| Rest of World OXLUMO |
|
0.85 % |
of total Revenue |
| Regeneron Pharmaceuticals |
|
3.97 % |
of total Revenue |
| Net revenues from collaborations |
|
7.03 % |
of total Revenue |
| Net revenues from collaborations Roche |
|
3.05 % |
of total Revenue |
| Net revenues from collaborations Regeneron Pharmaceuticals |
|
3.97 % |
of total Revenue |
| Net revenues from collaborations Other |
|
0.01 % |
of total Revenue |
| Global Strategic Collaboration Regeneron Pharmaceuticals Research Services Obligation |
|
0.57 % |
of total Revenue |
| Global Strategic Collaboration Regeneron Pharmaceuticals Other license programs |
|
3.4 % |
of total Revenue |
| Roche Roche Collaboration and License Agreement |
|
3.05 % |
of total Revenue |
| Roche Roche Development Services Obligation Roche Collaboration and License Agreement |
|
2.95 % |
of total Revenue |
| Roche Other Roche Collaboration and License Agreement |
|
0.11 % |
of total Revenue |
| Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration |
|
0.57 % |
of total Revenue |
| Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration |
|
3.4 % |
of total Revenue |
| |
On January 13 2025 the Alnylam Pharmaceuticals Inc provided following guidance
nnAlnylam Pharmaceuticals, Inc. Provides Preliminary 2024 Revenue Results and 2025 Forecast Alongside Pipeline Development Goalsnn
CAMBRIDGE, Massachusetts – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a trailblazer in the field of RNA interference (RNAi) therapeutics, has shared its preliminary results for global net product revenues for the fourth quarter and full year of 2024. The announcement highlights the financial performance of its key products: ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Moreover, the company has outlined its guidance for net product revenues in 2025, alongside its expectations for non-GAAP operating income and ambitious pipeline objectives.
Despite the absence o...
|
|
|
